November 21, 2010

Celldex Vaccine Meets Midstage Goal - Expect Sharp Rise in Share Price

Celldex Therapeutics Inc (CLDX) said its experimental vaccine for the the most common type of brain cancer met the main goal of extending survival time for patients without a progression of the disease in a mid-stage trial.

The company's injectable CDX-110 is designed to treat glioblastoma, the most common and aggressive type of brain cancer. It extended survival in a trial of 65 brain cancer patients.

The company plans a larger, clinical trial in the second half of next year. As a trader or as a long term position maker, one should focus on acquiring in the $4.50 to $5 range during pullbacks and then holding steady for 2-3 years. Initiate small positions and stay put. Also, be sure to set your mental loss tolerance well before you put money in.

No comments:

Post a Comment

Your comments and opinions here!

Join the Discussion